This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Bezafibrate Infarction Prevention Study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • double-blind, placebo-controlled trial
    • 3,090 patients with coronary heart disease (CHD) aged < 74 years (2,825 men, 265 women)
    • on entry total cholesterol 4.7 mmol/L-6.5mmol/L, triglyceride <3.4 mmol/L, HDL-c <1.16 mmol/L
    • treatment - bezafibrate 400mg per day or placebo
    • mean follow-up 6.2 years
  • no significant effect of bezafibrate on combined incidence of non-fatal MI or death from CHD 
    • post-hoc subgroup analysis indicated the possibility of a substantially greater benefit of bezafibrate in the subset of patients with a baseline plasma triglyceride > 2.25 mmol/L - in this subgroup event rate was 12.0% in the bezafibrate group and 19.7% in the placebo group (relative reduction of 39% (p=0.02))


  1. Circulation. 2000 Jul 4;102(1):21-7.
  2. The British Journal of Diabetes and Vascular Disease 2003; 3(3): 162-7.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.